Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,209.01
(
1.02%
)
US TECH 100
26,736.40
(
1.03%
)
Dow Jones
49,652.14
(
1.62%
)
Brent Oil
111.11
(
0.68%
)
Bitcoin
76,454.45
(
0.16%
)
News Focus
News Focus
Post# of 257473
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122916
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Whalatane post# 204912

Tuesday, 10/04/2016 1:17:14 PM

Tuesday, October 04, 2016 1:17:14 PM

Post# of 257473
OCRX-You appear to be conflating two trials. The phase-2a trial in ALF being conducted by NIH is the one that recently completed enrollment (#msg-125308176).

OCRX's own phase-2b (STOP-HE) is still enrolling patients; the goal is to have the full 230 patients enrolled by the end of 2016 (http://ir.ocerainc.com/common/download/download.cfm?companyid=ABEA-5YQ58G&fileid=908760&filekey=5B80A6F3-FECE-4F88-A48B-24CA50A1EF11&filename=Ocera_Presentation_Sep_2016.pdf ).

STOP-HE is the trial that will almost certainly be market-moving for the stock. Data are expected in 1Q17.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today